The National Eye Institute of the US National Institutes of Health (NIH) have announced a winner of their ambitious competition for researchers to build a… Read More »National Eye Institute (NEI) announces winner of research competition to develop a 3-D retina organoid
by Dr. Gearóid Tuohy Dear EURETINA Members, A very warm welcome to the October 16th, 2017 edition of EURETINA’s web-based digital magazine, “EURETINA… Read More »October 16th, 2017: “EURETINA-Brief”© Issue No. 163
by Dr. Gearóid Tuohy Dear EURETINA Members, A very warm welcome to the October 3rd, 2017 issue of our EURETINA Brief, a… Read More »October 3rd, 2017: “EURETINA-Brief”- Special Edition – Issue No. 162
Nightstar Therapeutics Ltd., a retinal gene therapy company spun out of the University of Oxford, UK, has filed a Form-1 with the United States SEC… Read More »University of Oxford retinal gene therapy company, Nightstar Therapeutics Ltd., files application to float on US NASDAQ.
A systematic review and meta-analysis to determine whether or not taking antioxidant vitamin or mineral supplements, or both, prevent the development of AMD has found… Read More »Systematic review of antioxidant vitamin and mineral use in preventing AMD suggests no benefit when analysed in >76,000 people
Research, reported in EURETINA’s professional journal, Ophthalmologica, has shown that a treat-and-extend (“TAE”) regimen using aflibercept for typical AMD appears effective for improving AMD and… Read More »Research published in Ophthalmologica shows aflibercept “treat and extend” (TAE) protocol is efficacious in typical AMD patients.
by Dr. Gearóid Tuohy Dear EURETINA Members, A very warm welcome to the September 16th, 2017 edition of EURETINA’s web-based digital magazine, “EURETINA… Read More »September 16th, 2017: “EURETINA-Brief”© Issue No. 161
Applied Genetic Technologies Corp. (NASDAQ: AGTC), a gene therapy company based in Gainesville, Florida, has announced the submission of an Investigational New Drug (IND) application… Read More »AGTC Inc. in Florida files an investigational new drug application for X-linked retinitis pigmentosa
The results of long-term use of aflibercept in patients with macular edema has inidcated that the need for retreatment appears to be substantially reduced in… Read More »Long-term outcomes with aflibercept in diabetic macular edema (DME) – 5 year outcomes reported through extension of previous study
A Nature editorial has called for increased support from research scientists into translational medicine, specifically in regards to cutting edge and novel technologies now seeking… Read More »Expert research scientists in demand to support evaluation of new drug approvals for novel technologies, including retinal stem cell and gene therapies